Investigators in the Division of Hematology’s Blood Cancer Program are actively engaged in multiple research activities aimed at improving outcomes for patients with blood cancers and related disorders. These studies are wide-ranging and involve extensive collaboration between laboratory scientists and physicians. Our work is funded by the National Cancer Institute (NCI), the American Cancer Society (ACS), the Leukemia and Lymphoma Society (LLS), and numerous other foundations and industry sources.
      A key strength of our research group is its highly collaborative and cross-disciplinary nature, which provides an ideal environment in which to develop new therapies. The Hematology Clinical Trials Unit (HCTU) plays an integral role in conducting the clinical research components of the division and have made bringing bench to bedside research a huge divisional success. The HCTU is comprised of 32 employees, and their dedication and investment each day is seen and felt by all patients that have and will participate in a clinical trial.